 After the acquisition of Arana, Research and Development operations continued in Sydney, Australia.In 1999 Cephalon settled a lawsuit for $17 million in which it had faced claims that Baldino and other company executives had overstated the potential for a drug aimed at treating amyotrophic lateral sclerosis (Lou Gehrig's disease).In addition, the Federal Trade Commission filed suit against Cephalon, stating that it had made "illegal deals with generic drug companies to delay generic competition to Provigil", an accusation that Cephalon has reportedly disputed.